Risk factors for de novo hepatitis B during solid cancer treatment

BACKGROUND: Reactivation of hepatitis B virus (HBV) during anticancer treatment is a critical issue. When treating patients with solid tumors, it is unclear whether specific cancer types or treatments affect HBV reactivation in hepatitis B surface antigen (HBsAg)-negative and hepatitis B core antibo...

Descripción completa

Detalles Bibliográficos
Autores principales: Sugimoto, Rie, Furukawa, Masayuki, Senju, Takeshi, Aratake, Yoshihusa, Shimokawa, Mototsugu, Tanaka, Yuki, Inada, Hiroki, Noguchi, Tatsuya, Lee, Lingaku, Miki, Masami, Maruyama, Yuji, Hashimoto, Risa, Hisano, Terumasa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Retrospective Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760444/
https://www.ncbi.nlm.nih.gov/pubmed/33392307
http://dx.doi.org/10.12998/wjcc.v8.i24.6264

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760444/
https://www.ncbi.nlm.nih.gov/pubmed/33392307
http://dx.doi.org/10.12998/wjcc.v8.i24.6264

Ejemplares similares